A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder
收藏DataCite Commons2025-01-20 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008008/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1,
2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children
with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.
提供机构：
Vivli
创建时间：
2022-06-23
